Lipid raft-regulated IGF-1R activation antagonizes TRAIL-induced apoptosis in gastric cancer cells

Resistance to TRAIL Is Mediated by DARPP-32 in Gastric Cancer

(2012) A. Belkhiri et al.   CLINICAL CANCER RESEARCH

TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells

(2012) Ling Xu et al.   EUROPEAN JOURNAL OF CANCER

Targeting the Glyoxalase Pathway Enhances TRAIL Efficacy in Cancer Cells by Downregulating the Expression of Antiapoptotic Molecules

(2012) H. Taniguchi et al.   MOLECULAR CANCER THERAPEUTICS

A Death Effector Domain Chain DISC Model Reveals a Crucial Role for Caspase-8 Chain Assembly in Mediating Apoptotic Cell Death

(2012) Laura S. Dickens et al.   MOLECULAR CELL

Gastric carcinogenesis

(2011) Jan Bornschein et al.   LANGENBECKS ARCHIVES OF SURGERY

2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression

(2011) C. Stolfi et al.   MOLECULAR CANCER THERAPEUTICS

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

(2010) T Trarbach et al.   BRITISH JOURNAL OF CANCER

Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: A new potential therapy for the treatment of melanoma

(2010) Thomas B. Karasic et al.   EXPERIMENTAL CELL RESEARCH

Phosphoinositide 3-kinase/Akt and nuclear factor κB pathways are involved in tumor necrosis factor-related apoptosis-inducing ligand resistance in human gastric cancer cells

(2010) Liu   Molecular Medicine Reports

Lipid rafts enriched in phosphatidylglucoside direct astroglial differentiation by regulating tyrosine kinase activity of epidermal growth factor receptors

(2009) Masami O. Kinoshita et al.   BIOCHEMICAL JOURNAL

IGF-1 receptor transactivation mediates Src-dependent cortactin phosphorylation in response to angiotensin IIThis article is one of a selection of papers published in a special issue celebrating the 125th anniversary of the Faculty of Medicine at the University of Manitoba.

(2009) Peter Zahradka et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin

(2009) Y. Adachi et al.   CARCINOGENESIS

Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts

(2009) Ling Xu et al.   FEBS LETTERS

Insulin-like growth factor-I-stimulated Akt phosphorylation and oligodendrocyte progenitor cell survival require cholesterol-enriched membranes

(2009) Robert J. Romanelli et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Heterogeneity of Receptor Function in Colon Carcinoma Cells Determined by Cross-talk between Type I Insulin-like Growth Factor Receptor and Epidermal Growth Factor Receptor

(2008) Y. P. Hu et al.   CANCER RESEARCH

Src and ADAM-17-Mediated Shedding of Transforming Growth Factor-  Is a Mechanism of Acute Resistance to TRAIL

(2008) S. Van Schaeybroeck et al.   CANCER RESEARCH

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

(2008) F. Anthony Greco et al.   LUNG CANCER